Cargando…

Tackling Resistance to Cancer Immunotherapy: What Do We Know?

Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gondhowiardjo, Soehartati A., Handoko, Jayalie, Vito Filbert, Apriantoni, Riyan, Barata, Andreas Ronald, Senoaji, Fajar, Utami, IGAA Jayanthi Wulan, Maubere, Ferdinand, Nuryadi, Endang, Giselvania, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570938/
https://www.ncbi.nlm.nih.gov/pubmed/32911646
http://dx.doi.org/10.3390/molecules25184096
_version_ 1783597062738149376
author Gondhowiardjo, Soehartati A.
Handoko,
Jayalie, Vito Filbert
Apriantoni, Riyan
Barata, Andreas Ronald
Senoaji, Fajar
Utami, IGAA Jayanthi Wulan
Maubere, Ferdinand
Nuryadi, Endang
Giselvania, Angela
author_facet Gondhowiardjo, Soehartati A.
Handoko,
Jayalie, Vito Filbert
Apriantoni, Riyan
Barata, Andreas Ronald
Senoaji, Fajar
Utami, IGAA Jayanthi Wulan
Maubere, Ferdinand
Nuryadi, Endang
Giselvania, Angela
author_sort Gondhowiardjo, Soehartati A.
collection PubMed
description Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward.
format Online
Article
Text
id pubmed-7570938
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75709382020-10-28 Tackling Resistance to Cancer Immunotherapy: What Do We Know? Gondhowiardjo, Soehartati A. Handoko, Jayalie, Vito Filbert Apriantoni, Riyan Barata, Andreas Ronald Senoaji, Fajar Utami, IGAA Jayanthi Wulan Maubere, Ferdinand Nuryadi, Endang Giselvania, Angela Molecules Review Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward. MDPI 2020-09-08 /pmc/articles/PMC7570938/ /pubmed/32911646 http://dx.doi.org/10.3390/molecules25184096 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gondhowiardjo, Soehartati A.
Handoko,
Jayalie, Vito Filbert
Apriantoni, Riyan
Barata, Andreas Ronald
Senoaji, Fajar
Utami, IGAA Jayanthi Wulan
Maubere, Ferdinand
Nuryadi, Endang
Giselvania, Angela
Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title_full Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title_fullStr Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title_full_unstemmed Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title_short Tackling Resistance to Cancer Immunotherapy: What Do We Know?
title_sort tackling resistance to cancer immunotherapy: what do we know?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570938/
https://www.ncbi.nlm.nih.gov/pubmed/32911646
http://dx.doi.org/10.3390/molecules25184096
work_keys_str_mv AT gondhowiardjosoehartatia tacklingresistancetocancerimmunotherapywhatdoweknow
AT handoko tacklingresistancetocancerimmunotherapywhatdoweknow
AT jayalievitofilbert tacklingresistancetocancerimmunotherapywhatdoweknow
AT apriantoniriyan tacklingresistancetocancerimmunotherapywhatdoweknow
AT barataandreasronald tacklingresistancetocancerimmunotherapywhatdoweknow
AT senoajifajar tacklingresistancetocancerimmunotherapywhatdoweknow
AT utamiigaajayanthiwulan tacklingresistancetocancerimmunotherapywhatdoweknow
AT maubereferdinand tacklingresistancetocancerimmunotherapywhatdoweknow
AT nuryadiendang tacklingresistancetocancerimmunotherapywhatdoweknow
AT giselvaniaangela tacklingresistancetocancerimmunotherapywhatdoweknow